Vosaroxin
- Generic Name
- Vosaroxin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N5O4S
- CAS Number
- 175414-77-4
- Unique Ingredient Identifier
- K6A90IIZ19
- Background
Vosaroxin is under investigation for the treatment of Leukemia, Myeloid, Acute.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
- Conditions
- Interventions
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 9
- Registration Number
- NCT03338348
- Locations
- 🇩🇪
University Hospital Ulm, Ulm, Germany
🇩🇪Kliniken Essen-Süd, Evang. Krankenhaus Essen-Werden gGmbH, Essen, Germany
🇩🇪Klinikum Oldenburg, Klinik für Innere Medizin II, Oldenburg, Germany
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT02658487
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 3100
- Registration Number
- NCT02416388
- Locations
- 🇫🇷
CH Amiens Hôpital Sud, Amiens, France
🇫🇷CHU Angers, Angers, France
🇫🇷CH Victor Dupouy, Argenteuil, France
Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 10
- Registration Number
- NCT01980056
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 35
- Registration Number
- NCT01913951
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 66
- Registration Number
- NCT01893320
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Sunesis Pharmaceuticals
- Target Recruit Count
- 113
- Registration Number
- NCT00607997
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸University of MO Ellis Fischel Cancer Center, Columbia, Missouri, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Sunesis Pharmaceuticals
- Target Recruit Count
- 75
- Registration Number
- NCT00246662
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.